Tvardi Therapeutics Stock Rating: Cantor Fitzgerald Reiterates Neutral

AI Summary

Cantor Fitzgerald has reiterated a Neutral rating on Tvardi Therapeutics (TVardi). This decision reflects the firm's assessment of the company's current performance and market conditions. Specific financial metrics or quantitative analyses were not disclosed in the report. The ongoing market performance of TVardi may be influenced by this stance, but no definitive figures or outlooks were provided to suggest short-term changes.